

**QCDR Measure:**

IRIS-11: Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity

**National Quality Strategy Domain:**

Effective Clinical Care

**Measure Type:**

Outcome

**Description:**

Percentage of patients with a diagnosis of nonexudative age-related macular degeneration and taking AREDS supplements with of loss of less than 0.3 logMar of visual acuity within the past 12 months.

**Instructions:**

This measure is to be reported a minimum of **once per reporting period** for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with nonexudative age-related macular degeneration (in either one or both eyes) will submit this measure.

**Denominator:**

All patients aged 18 years or older with a diagnosis of nonexudative AMD and documentation of laterality (OD, OS, OU)

Denominator Criteria**Patients aged  $\geq 18$  years**

AND

**Diagnosis of nonexudative age-related macular degeneration**

ICD-9 [for use 1/1/2015 – 9/30/2015]

- Nonexudative age-related macular degeneration (ICD-9: 362.51)

ICD-10 [for use 10/1/2015 – 12/31/2015]

- Nonexudative age-related macular degeneration (ICD-10: H35.31)

AND

**Taking antioxidant supplements**

**Numerator:**

Patients with two or more recorded visual acuity values within the past 12 months; loss of visual acuity less than 0.3 logMar. Visual acuity of the eye with nonexudative AMD should be reported.

Numerator Options:

Performance Met: Patients who achieved a loss in visual acuity of  $\leq 0.3$  logMar

Performance Not Met: Patients who did not achieve a loss in visual acuity of  $\leq 0.3$  logMar

**Improvement Notation:**

Higher score indicates better performance